AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25834203
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ‐SC) monotherapy
Trial: 25834203
Drug: Intravenous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous tocilizumab (TCZ‐IV) monotherapy, 8 mg/kg every 4 weeks
Trial: 22471559
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg daily
Trial: 26510725
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily
Trial: 12774231
Drug: Four tasks
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four tasks resulting from a factorial combination of two types of judgment and two judgment-to-response mappings
Trial: 11361054
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg for 24 days with simvastatin 40 mg on Days 15-24
Trial: 11361054
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg for 10 days
Trial: 11361054
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg for 24 days with simvastatin 80 mg on Days 15-24
Trial: 11361054
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg for 10 days
Trial: 9624541
Drug: Enoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (400 mg)
Trial: 8792486
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg)
Trial: 8033544
Drug: 1% SLG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% SLG solution
Trial: 8033544
Drug: 1% surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% surfactant mixture solutions (M1, M2, M3)
Trial: 8033544
Drug: 1% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% SLS solution
Trial: 21443416
Drug: Probiotic fermented
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic fermented milk (500 ml daily containing at least 5 × 10(7) CFU/ml of Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5, and Bifidobacterium lactis Bb12)
Trial: 16611288
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 4000 (0.50 g/kg)
Trial: 16611288
Drug: Lactulose (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (1.5 g/kg)
Trial: 2220725
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg qid)
Trial: 26588357
Drug: Implant placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant placement (IMP)
Trial: 15125846
Drug: Single caudal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single caudal epidural injection of 20 ml containing bupivacaine and tramadol
Trial: 15125846
Drug: Single caudal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single caudal epidural injection of 20 ml of normal saline
Trial: 9856165
Drug: Withholding albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding albumin or administration of crystalloid fluids
Trial: 24731899
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) for headache pain management, 8-week duration
Trial: 23727917
Drug: Dexmedetomidine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 3 µg
Trial: 9502454
Drug: piperacillin-tazobactam (TAZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin-tazobactam (TAZ; 4 g/0.5 g q.i.d.) + amikacin (7.5 mg/kg b.i.d.)
Trial: 9502454
Drug: ceftazidime (CAZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftazidime (CAZ; 1 g q.i.d.) + amikacin (7.5 mg/kg b.i.d.)
Trial: 8310997
Drug: Yogurt enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yogurt enriched with Bifidobacterium longum and 5 g lactulose/L (A)
Trial: 3402355
Drug: urapidil 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil 120 mg once daily
Trial: 3402355
Drug: urapidil 60
RxNorm normalized name: urapidil 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil 60 mg twice daily
Trial: 25335248
Drug: Scraping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping therapy (44 cases)
Trial: 25335248
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (41 cases)
Trial: 25335248
Drug: Both scraping
RxNorm normalized name: Sarapin
DrugBank: Sarracenia Purpurea (DB13965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both scraping and acupuncture therapies
Trial: 25335248
Drug: Scraping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping therapy
Trial: 20631341
Drug: 3B(90)E(500)P (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3B(90)E(500)P (30 kU bleomycin on days 1, 8, and 15; 100 mg/m(2) etoposide on days 1‐5; 20 mg/m(2) cisplatin on days 1‐5; n = 83)
Trial: 20631341
Drug: 4B(30)E(360)P (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4B(30)E(360)P (30 kU bleomycin on day 1; 120 mg/m(2) etoposide on days 1‐3; 100 mg/m(2) cisplatin on day 1; n = 83)
Trial: 16804655
Drug: Piperacillin/tazobactam (P/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (P/T) at 4 g/0.5 g
Trial: 16804655
Drug: Imipenem/cilastatin (I/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (I/C) at 1 g/1 g
Trial: 11544831
Drug: Endolymphic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endolymphic infusion of immunomodulator
Trial: 11544831
Drug: Regional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional infusion of considerable doses of cytostatic mixes
Trial: 31418585
Drug: Abaloparatide 80
RxNorm normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide 80 µg daily
Trial: 31418585
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 µg daily
Trial: 26242335
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with an exercise program
Trial: 2944534
Drug: Ethinyloestradiol 50
RxNorm normalized name: Ethinyloestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyloestradiol 50 micrograms/cyproterone acetate 50 mg
Trial: 30770539
Drug: Slightly sweet
RxNorm normalized name: Oracoat Xylimelts Dry Mouth Slightly Sweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slightly sweet lipid-based nutrient supplement (LNS)
Trial: 26097440
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.4 g · kg(‐1) body weight)
Trial: 19139776
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (n=27) received 15 ml (102.5mg) of 0.75% solution
Trial: 19139776
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (n=27) received 10 ml (75 mg) of 0.75% solution
Trial: 19139776
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (n=27) received 10 ml (50mg) 0.5% ropivacaine
Trial: 18232268
Drug: Iodised salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodised salt plus weekly 70 mg iron supplement (IS + iron)
Trial: 18232268
Drug: Iodised salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodised salt (IS) plus weekly placebo (control group)
Trial: 15111940
Drug: Physical methods,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical methods, especially with the use of biological feedback
Trial: 15111940
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pharmacological and physical treatments
Trial: 9741655
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (HBB) 10 mg
Trial: 9741655
Drug: Atropine sulphate
RxNorm normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulphate 0.4 mg
Trial: 30864532
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment alternative to hospital care (experimental group)
Trial: 30864532
Drug: Conventional service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional service model without home treatment (control group)
Trial: 28632865
Drug: Cetuximab combined
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab combined with mFOLFOX6 or FOLFIRI chemotherapy
Trial: 28632865
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with mFOLFOX6 or FOLFIRI chemotherapy
Trial: 17304888
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical application
Trial: 17031654
Drug: Sequential ureteric
RxNorm normalized name: Bos taurus ureter preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential ureteric catheter insertion
Trial: 10077720
Drug: Bioresonance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioresonance therapy (10 sessions)
Trial: 10077720
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy (after bioresonance therapy)
Trial: 10077720
Drug: Bioresonance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioresonance therapy (after speech therapy)
Trial: 7740939
Drug: Half‐thickness patellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half‐thickness patellar tendon graft augmented with the Kennedy Ligament Augmentation Device (LAD)
Trial: 2184133
Drug: Disulfiram 100
RxNorm normalized name: disulfiram 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 100 mg
Trial: 2184133
Drug: Disulfiram 400
RxNorm normalized name: disulfiram 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 400 mg
Trial: 21703848
Drug: Preoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment according to the localised-disease protocol
Trial: 21703848
Drug: Preoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment according to the metastatic-disease protocol
Trial: 19829096
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 international units daily for 12 weeks)
Trial: 16249540
Drug: Ruboxistaurin 32
RxNorm normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin 32 mg/day for 1 year
Trial: 8703664
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg daily for 15 days
Trial: 29243058
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ondansetron IV (group O)
Trial: 29243058
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml saline (group S)
Trial: 10791526
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment schedule (10 daily injections of 2.2 mg/kg)
Trial: 10791526
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment schedule (26-day regimen of melarsoprol with doses increasing from 1.2 to 3.6 mg/kg)
Trial: 9289940
Drug: Tensiomin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tensiomin (50 mg)
Trial: 9289940
Drug: Tensiomin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tensiomin (100 mg)
Trial: 9289940
Drug: Capoten (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capoten (50 mg)
Trial: 9289940
Drug: Capoten (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capoten (100 mg)
Trial: 9289940
Drug: Lopirin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopirin (50 mg)
Trial: 3602016
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily regimen of combined inhalation of salbutamol and beclomethasone dipropionate from a single inhaler
Trial: 3602016
Drug: 4-times daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-times daily regimen of combined inhalation of salbutamol and beclomethasone dipropionate from a single inhaler
Trial: 30514741
Drug: Hill's Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hill's Prescription Diet k/d Feline with chicken, dry
Trial: 27645692
Drug: Metabolic tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic tumor volume (MTV) pre-treatment >32 mL
Trial: 27645692
Drug: Higher tMTV-pre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher tMTV-pre (per 10-mL increase)
Trial: 27645692
Drug: Radiotherapy dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy dose (≤60 Gy vs. 61-69 Gy or ≥70 Gy) in patients with tMTV-pre >32 mL
Trial: 27645692
Drug: Radiotherapy dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy dose in patients with tMTV-pre ≤32 mL
Trial: 14501447
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (Prednisone 60mg and taper)
Trial: 28503770
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levetiracetam (LEVIV) 20 mg/kg
Trial: 28503770
Drug: Intranasal crushed
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal crushed immediate release levetiracetam (LEVCIR) 30 mg/kg
Trial: 28503770
Drug: Intranasal crushed
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal crushed extended release levetiracetam (LEVCER) 30 mg/kg
Trial: 22682875
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CoQ10 + 300 IU vitamin E
Trial: 21347907
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral group therapy
Trial: 21347907
Drug: Smoker control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoker control group without treatment
Trial: 17311241
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment for stress urinary incontinence
Trial: 7941195
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg SIN-1
Trial: 7941195
Drug: P/P (papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P/P (papaverine 15 mg/mL and phentolamine 0.5 mg/mL)
Trial: 22917813
Drug: Enzastaurin (1125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (1125 mg on Day 1 followed by 500 mg daily)
Trial: 12957426
Drug: Short-term vitamin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term vitamin C administration (3 g intravenous infusion)
Trial: 12957426
Drug: Long-term vitamin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term vitamin C treatment (2 g daily for 3 months)
Trial: 12957426
Drug: Long-term vitamin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term vitamin C treatment (2 g daily for 2 years)
Trial: 12957426
Drug: Short-term vitamin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term vitamin C infusion (3 g intravenous infusion)
Trial: 12957426
Drug: Short-term vitamin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term vitamin C treatment (3 g intravenous infusion)
Trial: 1522084
Drug: Miconazole varnish
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole varnish (single-dose application)
Trial: 1522084
Drug: Miconazole gel
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole gel (applied three times/day for 15 days)
Trial: 30106266
Drug: Ifenprodil (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifenprodil (60 mg per day for 3 months)
Trial: 30106266
Drug: Control (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (600 mg ascorbic acid and calcium pantothenate per day for 3 months)
Trial: 25253123
Drug: Prior use
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior use of inhaled steroids
Trial: 20467288
Drug: Raltegravir-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir-based therapy
Trial: 20467288
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitor-based therapy
Trial: 18638004
Drug: Mirodenafil 50
RxNorm normalized name: Mirodenafil
DrugBank: Mirodenafil (DB11792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirodenafil 50 mg
Trial: 10486418
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg intravenous)
Trial: 8666569
Drug: Buspirone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (15 to 45 mg/day)
Trial: 3899666
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg/day for 1 yr
Trial: 55529
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no further treatment)
Trial: 26524933
Drug: Epinephrine (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.33 mg/L) added to saline irrigation fluid
Trial: 20205481
Drug: Subcutaneous rehydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rehydration therapy (SCRT)
Trial: 20205481
Drug: Intravenous rehydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rehydration therapy (IVRT)
Trial: 16022023
Drug: Adjunctive local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive local delivery of extracts from Centella asiatica and Punica granatum
Trial: 16022023
Drug: Standard supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supportive periodontal therapy (SPT)
Trial: 12446187
Drug: Cheese containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cheese containing Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC 705, 5 x 15 g per day for 3 weeks
Trial: 8076229
Drug: Midazolam (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.07 mg.kg‐1 for <65 years, 0.06 mg.kg‐1 for ≥65 years)
Trial: 8076229
Drug: Diazepam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.15 mg.kg‐1 for <65 years, 0.11 mg.kg‐1 for ≥65 years)
Trial: 2531570
Drug: Calcipotriol 25
RxNorm normalized name: calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriol 25 micrograms/g
Trial: 2531570
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 micrograms/g
Trial: 2531570
Drug: Calcipotriol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 100 micrograms/g
Trial: 2531570
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with calcipotriol ointment
Trial: 26324362
Drug: XELOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX (oxaliplatin 130 mg/m² on day 1 and capecitabine 1,000 mg/m² twice daily on days 1 to 14 every 3 weeks for 6 months)